Tobacco smoking continues to be the primary cause of preventable mortality in the United
States. Despite the availability of smoking cessation aids, the majority of those trying to
quit smoking end up relapsing. Thus, there is a strong need to evaluate alternative treatment
targets such as orexin antagonists, which have shown promise in preclinical models at
reducing the motivational aspects of drug use.The current work will evaluate the influence of
orexin antagonism on several factors impacting the motivation to smoke.